Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

THERA-LEGO

Financiado

Commercial feasibility of a therapeutic approach to cancer based on LEGO antib...

Commercial feasibility of a therapeutic approach to cancer based on LEGO antibody recruiting glycodendrimers Cancer remains a major cause of mortality worldwide, with projections estimating that 40% of population will be diagnosed with a form of cancer during their lifetime. Despite significant progress in treatment modalities, current t... ver más

30/06/2022

UGA

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

UNIVERSITE GRENOBLE ALPES No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-06-30

ERC-2020-POC: Call for proposals for ERC Proof of...

I+D

Cerrada hace 4 años

0% 100% 100%

2 Participantes

UGA

150.00K€ | Lider

BARCELONA ELECTROMAGNETIC EN...

472.22K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 19 meses Fecha Inicio: 2020-11-27
Fecha Fin: 2022-06-30

Líder del proyecto

UNIVERSITE GRENOBLE ALPES No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Cancer remains a major cause of mortality worldwide, with projections estimating that 40% of population will be diagnosed with a form of cancer during their lifetime. Despite significant progress in treatment modalities, current therapeutic regimens are still deficient due to intolerable side effects, while stray cancer cells often escape destruction. Immunotherapy-based approaches certainly represent the most promising alternatives in this area although very limited approaches are available. In addition, major issues remain to be addressed such as the lack of efficiency and autoimmune toxicity for a large population of patients. In the ERC Consolidator grant LEGO, we have demonstrated that fully synthetic structures with unprecedented combinations have immunological properties against cancers. We have developed a molecular LEGO approach to construct Antibody Recruiting Glycodendrimers (ARGs) embedded with key structural parameters and capable of redirecting endogenous antibodies present in the human bloodstream against tumors without preliminary immunization. Among a variety ARGs, we have identified two lead compound that: 1/ recruit natural Abs with a cluster of oligosaccharides; 2/ target cancer receptors with a cluster of peptides; 3/ promote the formation of a ternary complex between natural Abs and cancer cells; 4/ promote up to 60% of cytotoxicity towards cancer cells in vitro. Within THERA-LEGO, we aim to investigate the commercial feasibility and the in vivo properties of our lead compounds (toxicity, stability, biodistribution, pharmacokinetics/dynamics, immunogenicity) in humanized mice models, to facilitate the transfer of the technology to a company and the initiation of clinical development. The work to be done in this project will advance our assets from a Technology Readiness Level (TRL) of 3 to 5 and will enable us to create an exploitation strategy (relying either on commercialization through own spin-off or licensing to a pharma company).

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores